Outpatient parenteral antibiotic therapy

Infections in Medicine

Volumn 21, Issue 10, 2004, Pages 496-504

  DeMaio, James ^a  

^a NONE

Author keywords

Antibiotic therapy; Outpatient

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; FLUCONAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ABDOMINAL ABSCESS; ABDOMINAL CRAMP; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; CELLULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL VENOUS CATHETER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED DRUG RELEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ABUSE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG STABILITY; ENDOCARDITIS; FEBRILE NEUTROPENIA; HEMATOCHEZIA; HOME CARE; HUMAN; INFECTION; INFUSION PUMP; INSURANCE; LAW; LEUKOCYTOSIS; LYME DISEASE; MEDICARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NEUTROPENIA; OSTEOMYELITIS; OUTPATIENT CARE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PYELONEPHRITIS; RETINITIS; SINUSITIS; STAPHYLOCOCCUS INFECTION;

EID: 13644258789     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Williams DN, Bosch D, Boots J, Schneider J. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Clin Ther. 1993;15:169-179.
2. Bernard L, El-Hajj, Pron B, et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther. 2001; 26:445-451.
3. Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis. 1999;29:1394-1399.
4. Talcott JA, Whalen A, Clark J, et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107-114.
5. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2004;38:1651-1672.
6. Nolet BR. Patient selection in outpatient parenteral antimicrobial therapy. Infect Dis Clin North Am. 1998;12:835-847.
7. Williams DN, Raymond JL. Practice guidelines for community-based parenteral anti-infective therapy. Infect Dis Clin North Am. 1998;12:1009-1021.
8. Mortlock NJ, Schleis T. Outpatient parenteral antimicrobial therapy technology. Infect Dis Clin North Am. 1998;12:861-878.
9. Schleis TG, Tice AD. Selecting infusion devices for use in ambulatory care. Am J Health Sys Pharm. 1996;53:868-877.
10. Gilbert DN, Dworkin RJ, Raber SR, Leggett JE. Outpatient parenteral antimicrobial-drug therapy. N Engl J Med. 1997;337:829-838.
11. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am. 1998;12:849-860.
12. Slavik RS, Jewesson PJ. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet. 2003;42:793-817.
13. Cohen E, Dadashev A, Drucker M, et al. Once-daily versus twice-daily intravenous administration of vancomycin for infection in hospitalized patients. J Antimicrob Chemother. 2002;49: 155-160.
14. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479-501.
15. Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther. 2002; 24:1090-1104.
16. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and phamacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002;22:471-483.
17. Rappaz I, Decosterd LA, Bille J, et al. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr. 2000;159: 919-925.
18. Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. Am J Health Syst Pharm. 2003;60:2321-2327.
19. Hoffman-Terry ML, Fraimow HS, Fox TR, et al. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med. 1999;106:44-49.
20. Tice AD. Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am. 1998;12:903-919.
21. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am. 1998;12:879-901.
22. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis. 2001;33:203-209.
23. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18: 3038-3051.
24. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515-521.